Opdivo
The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.
NICE Recommends Opdivo, Yervoy in First-Line MSI-High, dMMR Colorectal Cancer
The decision is based on results from the Phase III CheckMate 8HW and the Phase II CheckMate 142 trials.
FDA Approves Opdivo, Yervoy as First-Line Treatment for MSI-High, dMMR Colorectal Cancer
The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.
The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.
BMS Seeking FDA Approval for Opdivo-Yervoy in Frontline MSI-High, dMMR Advanced Colorectal Cancer
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Jul 26, 2024
Apr 25, 2024